MicrobiologybioRxiv
SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1
J. L. M. Law, M. Logan, M. Joyce…·M. Houghton
This study shows that recombinant SARS-CoV-2 RBD induces neutralizing antibodies against variant strains and SARS-CoV-1, suggesting its potential as a vaccine candidate or booster.
DOI 10.1016/j.vaccine.2021.08.081